---
$id: https://graph.org.ai/products/commodity/51201569
$type: Product
source: UNSPSC
code: "51201569"
title: "Atlizumab or tocilizumab"
class: "51201500"
classTitle: "Immunosuppressants"
family: "51200000"
familyTitle: "Immunomodulating drugs"
segment: "51000000"
segmentTitle: "Pharmaceutical Products incl. Contraceptives and Vaccines"


---

# Atlizumab or tocilizumab

**UNSPSC Code**: 51201569
**Class**: [Immunosuppressants](Immunosuppressants.mdx)
**Family**: [Immunomodulating drugs](../Immunomodulating drugs.mdx)
**Segment**: [Pharmaceutical Products incl. Contraceptives and Vaccines](../../Pharmaceutical Products incl. Contraceptives and Vaccines.mdx)

This classification denotes a monoclonal antibody with the molecular formula C6428H9976N1720O2018S42, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier I031V2H011, more generally known as tocilizumab. European Medicines Agency schedules tocilizumab in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB20313. The term TOCILIZUMAB is an International Non-Proprietary Name or INN. see WHO INN reference publication, Volume 18, no. 3, 2004, list 52. Atlizumab or tocilizumab bears US NLM identifiers UMLS ID C1609165 and NCI Concept Code C84217.

